Evidence map›Paper›PMID 39817679›Full record

ArticleCA: a cancer journal for clinicians

Cancer statistics, 2025.

Rebecca L Siegel, Tyler B Kratzer, Angela N Giaquinto, Hyuna Sung, Ahmedin Jemal

10 registry-linked trialsAbstract read
In one paragraph

Article in CA: a cancer journal for clinicians. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 10 registered trials, which are not on this map. Cited by 3,671 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3,671citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07045610 not yet recruitingnot on this map

Explore the Primary Resistance Mechanisms of Anaplastic Lymphoma Kinase Inhibitors

TypeobservationalSponsorNational Taiwan University HospitalRan2025 to 2028Enrolled20ConditionsALK-positive Advanced NSCLC Patients, Primary Resistance, NGSArmsre-biopsy tumor with primary ALK tKI resistance for NGS
NCT07214532 narecruitingnot on this map

SIgnatera-Guided Initiation of Adjuvant CDK4/6 Inhibitor in Intermediate Risk HR+ HER2- Breast Cancer

TypeinterventionalSponsorNatera, Inc.Ran2026 to 2037Enrolled725ConditionsBreast Neoplasms, Carcinoma, Ductal, Breast, Receptors, Estrogen (for ER-positive Requirement)ArmsctDNA-Guided Treatment Strategy
NCT07224789 recruitingnot on this map

Liquid Biopsy for Early Detection of Colorectal Cancer Using Circular RNA

TypeobservationalSponsorCity of Hope Medical CenterRan2025 to 2028Enrolled600ConditionsColorectal CancerArmscf-circRNA assay
NCT07224802 completednot on this map

An Exosome-based Liquid Biopsy Signature for Preoperative Identification of Occult Liver Metastasis in Patients With Pancreatic Ductal Adenocarcinoma

TypeobservationalSponsorCity of Hope Medical CenterRan2024 to 2026Enrolled372ConditionsPDAC - Pancreatic Ductal AdenocarcinomaArmsEXELiM assay (qRT-PCR validation), EXELiM small RNA sequencing
NCT07224815 recruitingnot on this map

Development of a cfDNA 5mC/5hmC-based Epigenetic Biomarker Panel to Predict Chemotherapy Efficacy in Metastatic Colorectal Cancer

TypeobservationalSponsorCity of Hope Medical CenterRan2024 to 2028Enrolled600ConditionsCRC (Colorectal Cancer)ArmscfDNA 5mC/5hmC Sequencing (EpiCORE Discovery Phase), EpiCORE Assay (Targeted Sequencing / qPCR Validation)
NCT07224841 recruitingnot on this map

Development of a cfDNA 5mC/5hmC-based Epigenetic Biomarker Panel to Identify Determinants of Response In VEGF/EGFR-targeted Therapy for Metastatic Colorectal Cancer

TypeobservationalSponsorCity of Hope Medical CenterRan2024 to 2028Enrolled500ConditionsCRC (Colorectal Cancer)ArmscfDNA 5mC/5hmC Sequencing (EpiDRIVE Discovery Phase), EpiDRIVE Assay (Targeted Sequencing / qPCR Validation)
NCT07321197 narecruitingnot on this map

Template Lymph Node Dissection for Tumor Control in High-Risk Renal Cell Carcinoma: A Prospective, Open-Label, Multicenter, Randomized Controlled Trial

TypeinterventionalSponsorTianjin Medical University Second HospitalRan2025 to 2033Enrolled220ConditionsRenal Cell Carcinoma (Kidney Cancer)ArmsTemplate Lymph Node Dissection, Selective Lymph Node Resection
NCT07321210 narecruitingnot on this map

Clinical Efficacy and Safety of Radical Nephroureterectomy With Versus Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma: A Multicenter, Prospective, Randomized Controlled Clinical Trial

TypeinterventionalSponsorTianjin Medical University Second HospitalRan2025 to 2032Enrolled150ConditionsUpper Tract Urothelial Carcinoma, Lymph Node DissectionArmsTemplate Lymph Node Dissection, Selective Lymph Node Resection
NCT07339384 nanot yet recruitingnot on this map

Circulating Tumor DNA Assessment in Early-Stage Endometrial Cancer (SIGNAL-EMC 101)

TypeinterventionalSponsorNatera, Inc.Ran2026 to 2034Enrolled1,010ConditionsEndometrial CancerArmsSignatera Genome ultra-sensitive ctDNA blood test
NCT07528066 recruitingnot on this map

The Impact of Downstaging on Robotic Surgical Outcomes After Neoadjuvant Chemo-Immunotherapy in Non-Small Cell Lung Cancer

TypeobservationalSponsorShanghai Chest HospitalRan2026 to 2027Enrolled200ConditionsNeoadjuvant Chemoimmunotherapy, Robotic Pulmonary Resection, Stage IIB-III NSCLCArmsRobotic-assisted surgery (RATS)
3 · Its place in the literature

Who cites it

3,671 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Curcumin in ovarian cancer: mechanistic insights and translational potential.Medical oncology (Northwood, London, England) · 2026
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

3,611 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Rebecca L SiegelCancer Surveillance Research, American Cancer Society, Atlanta, Georgia, USA.ORCID 0000-0001-5247-8522
Tyler B KratzerCancer Surveillance Research, American Cancer Society, Atlanta, Georgia, USA.ORCID 0000-0002-5618-6380
Angela N GiaquintoCancer Surveillance Research, American Cancer Society, Atlanta, Georgia, USA.ORCID 0000-0003-2548-9693
Hyuna SungCancer Surveillance Research, American Cancer Society, Atlanta, Georgia, USA.ORCID 0000-0002-8021-5997
Ahmedin JemalSurveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes using incidence data collected by central cancer registries (through 2021) and mortality data collected by the National Center for Health Statistics (through 2022). In 2025, 2,041,910 new cancer cases and 618,120 cancer deaths are projected to occur in the United States. The cancer mortality rate continued to decline through 2022, averting nearly 4.5 million deaths since 1991 because of smoking reductions, earlier detection for some cancers, and improved treatment. Yet alarming disparities persist; Native American people bear the highest cancer mortality, including rates that are two to three times those in White people for kidney, liver, stomach, and cervical cancers. Similarly, Black people have two-fold higher mortality than White people for prostate, stomach, and uterine corpus cancers. Overall cancer incidence has generally declined in men but has risen in women, narrowing the male-to-female rate ratio (RR) from a peak of 1.6 (95% confidence interval, 1.57-1.61) in 1992 to 1.1 (95% confidence interval, 1.12-1.12) in 2021. However, rates in women aged 50-64 years have already surpassed those in men (832.5 vs. 830.6 per 100,000), and younger women (younger than 50 years) have an 82% higher incidence rate than their male counterparts (141.1 vs. 77.4 per 100,000), up from 51% in 2002. Notably, lung cancer incidence in women surpassed that in men among people younger than 65 years in 2021 (15.7 vs. 15.4 per 100,000; RR, 0.98, p = 0.03). In summary, cancer mortality continues to decline, but future gains are threatened by rampant racial inequalities and a growing burden of disease in middle-aged and young adults, especially women. Continued progress will require investment in cancer prevention and access to equitable treatment, especially for Native American and Black individuals.

Indexed as

NeoplasmsAdolescentAdultAgedFemaleHumansIncidenceMaleMiddle AgedMortalityRegistriesUnited StatesYoung Adultcancer casescancer statisticsdeath ratesincidencemortality

Identifiers

PMID39817679
PMCPMC11745215

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

and 4 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.